1cP-MiPLA 200 mcg Blotters – Scientific Product Description

Introduction

1cP-MiPLA (1-cyclopropionyl-methyl-isopropyl-lysergamide) is a novel lysergamide compound that is being investigated in pharmacological and neurochemical studies. These 200 mcg blotters are intended for professional scientific use by recognized research institutions only.

Technical Specifications

• Chemical name: 1-cyclopropionyl-N-methyl-N-isopropyl-lysergamide
• Molecular formula: C₂₁H₂₇N₃O₂
• Molecular weight: 353.46 g/mol
• Dosage per blotter: 200 ± 7 mcg (HPLC verified)
• Blotter size: 6x6 mm with precision perforation
• Carrier medium: Pharmaceutical grade cellulose matrix
• Purity: ≥99% (UPLC-MS/MS)
• Stability: 36 months at -20°C in argon atmosphere

Research applications

The 1cP-MiPLA blotters are used for:

• Receptor binding studies on 5-HT₂A/2C receptors
• Comparative pharmacodynamics within the lysergamide class
• Metabolism research and pathway mapping in vitro
• Dose-response analyses in experimental models

Quality guarantees

Each batch contains:

• HPLC-DAD-ELSD analysis
• Q-TOF high-resolution mass spectrometry
• Homogeneity test (n=20)
• Residual solvent screening (GC-MS)
• Microbiological purity control

Safety regulations

Laboratory protocols

• Class II biological safety cabinet required
• Protective equipment: Tyvek suit, double nitrile gloves
• Explosion-proof storage environment required for bulk storage
• Access restriction for authorized personnel

First aid

• Eye contact: Rinse with water for at least 30 minutes.
• Skin or inhalation exposure: Seek immediate medical evaluation
• Contamination: Use of supplied specialized clean-up kit

Regulatory Framework

• Classified under the Dutch Opium Act (List I)
• WADA classified as a prohibited substance (category S6)
• Subject to EU regulation on new psychoactive substances
• Only allowed for laboratory research with a permit

Distribution conditions

• Minimum order quantity: 5 blotters (individually wrapped)
• Mode of transportation: Cryogenically cooled, with GPS tracking
• Documentation: EU-GMP production certificate and full analysis file
• Required qualification: GLP registration of purchasing institution

Reference material

• Brandt et al. (2022) – Journal of Psychopharmacology
• EMCDDA Risk Assessment Report – Q2 2023
• ICH Q3D – Guideline for Elemental Impurities

Legal Disclaimer

This product is intended exclusively for use by authorized scientific institutions in the context of legally recognized research. Any other use is prohibited and may have legal consequences under national and international regulations. The final responsibility lies with the buyer.

6-CL-ADBA 2-CMC 250mg pellets 2C-EF 2mg Capsules MEAI